Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.
Neuren Pharmaceuticals Limited announced an update on its ongoing share buy-back program, reporting the buy-back of 13,421 ordinary fully paid securities on the previous day, bringing the total to 3,635,139 securities bought back. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its equity base.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address significant unmet medical needs in these areas.
Average Trading Volume: 761,156
Technical Sentiment Signal: Buy
Current Market Cap: A$1.79B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue